This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2hyy

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2hyy.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2hyy.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2hyy| PDB=2hyy | SCENE= }}
{{STRUCTURE_2hyy| PDB=2hyy | SCENE= }}
-
'''Human Abl kinase domain in complex with imatinib (STI571, Glivec)'''
+
===Human Abl kinase domain in complex with imatinib (STI571, Glivec)===
-
==Overview==
+
<!--
-
Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanced-stage CML frequently fail to respond or lose their response to therapy owing to the emergence of drug-resistant mutants of the protein. More than 40 such point mutations have been observed in imatinib-resistant patients. The crystal structures of wild-type and mutant Abl kinase in complex with imatinib and other small-molecule Abl inhibitors were determined, with the aim of understanding the molecular basis of resistance and to aid in the design and optimization of inhibitors active against the resistance mutants. These results are presented in a way which illustrates the approaches used to generate multiple structures, the type of information that can be gained and the way that this information is used to support drug discovery.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17164530}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17164530 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17164530}}
==Disease==
==Disease==
Line 32: Line 36:
[[Category: Manley, P.]]
[[Category: Manley, P.]]
[[Category: Tyrosine kinase]]
[[Category: Tyrosine kinase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 06:52:59 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 05:07:04 2008''

Revision as of 02:07, 28 July 2008

Image:2hyy.png


PDB ID 2hyy

Drag the structure with the mouse to rotate
2hyy, resolution 2.40Å ()
Ligands:
Gene: ABL1 (Homo sapiens)
Activity: Non-specific protein-tyrosine kinase, with EC number 2.7.10.2
Related: 1iep, 1fpu
Resources: FirstGlance, OCA, RCSB, PDBsum
Coordinates: save as pdb, mmCIF, xml



Contents

Human Abl kinase domain in complex with imatinib (STI571, Glivec)

Template:ABSTRACT PUBMED 17164530

Disease

Known disease associated with this structure: Leukemia, Philadelphia chromosome-positive, resistant to imatinib OMIM:[189980]

About this Structure

2HYY is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia., Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW, Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006, Dec 13. PMID:17164530

Page seeded by OCA on Mon Jul 28 05:07:04 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2hyy"
Personal tools